Royalty Pharma (RPRX) Income from Non-Controlling Interests (2019 - 2026)

Royalty Pharma has disclosed Income from Non-Controlling Interests across 8 years of filings, most recently posting $173.6 million for Q1 2026.

• Income from Non-Controlling Interests for Q1 2026 came in at $173.6 million, down 11.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $491.0 million (down 27.37% YoY), and the FY2025 annual result was $553.2 million, up 17.26% from the prior year.
• Income from Non-Controlling Interests came in at $173.6 million for Q1 2026 at Royalty Pharma, up from $141.7 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $262.4 million in Q3 2024 to a low of -$153.9 million in Q4 2022.
• The 5-year median for Income from Non-Controlling Interests is $126.1 million (2024), against an average of $112.4 million.
• Across the five-year window, Income from Non-Controlling Interests slumped 436.37% in 2022 and soared 2255.39% in 2025, its largest moves.
• Royalty Pharma's Income from Non-Controlling Interests stood at -$153.9 million in 2022, then jumped by 245.02% to $223.2 million in 2023, then tumbled by 43.5% to $126.1 million in 2024, then gained by 12.34% to $141.7 million in 2025, then grew by 22.48% to $173.6 million in 2026.
• The last three Income from Non-Controlling Interests figures came in at $173.6 million (Q1 2026), $141.7 million (Q4 2025), and $156.0 million (Q3 2025), per Business Quant data.